Aura Biosciences Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Aura Biosciences Inc reported a Q3 2025 net loss of $26.1 million, up from $21.0 million last year, with operating expenses at $27.9 million due to increased R&D costs. Despite losses, the company raised $69.9 million through a follow-on offering, boosting total assets to $190.0 million. Investments focus on bel-sar, in Phase 3 trials for choroidal melanoma. Additional paid-in capital rose to $611.5 million. Aura aims for regulatory approvals and commercialization, optimistic about bel-sar's potential and exploring new therapeutic areas.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments